{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124458","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.652712+00:00","generated_at":"2026-05-30T01:49:42.247559+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ultragenyx reports positive Phase 1/2 data for GTX-102 in Angelman syndrome; Phase 3 Aspire study well powered","bullets":["Week 48 Bayley-4 Cognition GSV mean change +6.7 vs minimally important difference +5 (n=40).","Phase 3 primary endpoint Bayley-4 Raw score mean change +10.9 from baseline.","Study >95% powered to detect treatment effect even with up to 3x higher sham response.","MDRI net response +2.0 (p<0.0001); 80% of patients achieved net improvement in at least one domain.","Phase 3 Aspire will enroll ~120 patients with full maternal UBE3A deletion; 48-week primary analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124458","json":"https://secwatch.observer/filing/0000950170-24-124458.json","markdown":"https://secwatch.observer/filing/0000950170-24-124458.md","text":"https://secwatch.observer/filing/0000950170-24-124458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024124458/0000950170-24-124458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017024124458/rare-20241109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:49:42.247559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}